ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI New Advisory Group Named On special Populations

June 25, 1999

In Brief: Cavenee Is President-elect of AACR; Coffey To Succeed Strong As President

April 11, 1997

Fibrolast Interferon Contract Signed

May 2, 1980

Childhood cancer Death Rates Decline, Incidence Stable, NCI Says In Report

July 30, 1999

Push to Get Exceptions, Adjustments For Clinical Research In DRG Regulations Gaining Momentum

July 22, 1983

Also in this issue: ODAC Votes To Strip Breast Cancer Indication From Avastin

July 23, 2010